C4 Therapeutics, Inc. — Director's Dealing 2021

Sep 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-09-10

Reporting Person: Prokupets Elena (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-10	Common Stock	S	1230	$50.0008	Disposed	87344	Indirect
2021-09-10	Common Stock	S	1320	$50.0075	Disposed	591553	Indirect
2021-09-13	Common Stock	S	3330	$50.0692	Disposed	84014	Indirect
2021-09-13	Common Stock	S	3330	$50.0731	Disposed	588223	Indirect

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2021.

F4: Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.54. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.